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Introduction: Tamoxifen is one of the most common treatment opportunities for
hormonal positive breast cancer. Despite its good tolerability, patients demonstrate
decreasing adherence over years impacting on therapeutic success. PBPK modeling
was applied to demonstrate the impact of drug holidays on plasma levels of tamoxifen
and its active metabolite endoxifen for different CYP2D6 genotypes.
Materials and Methods: A virtual study with 24,000 patients was conducted in order
to investigate the development of tamoxifen steady-state kinetics in patient groups of
different CYP2D6 genotypes. The impact of drug holidays on steady-state kinetics was
investigated assuming changing drug holiday scenarios.
Results: Drug holidays in CYP2D6 extensive and intermediate metabolizers (EMs, IMs)
exceeding 1 month lead to a decrease of endoxifen steady-state trough levels below the
5th percentile of the control group. Assuming drug holidays of 1, 2, or 3 months and
administering a fixed-dose combination of 20mg tamoxifen and 3mg endoxifen EMs
demonstrated re-established endoxifen steady-state trough levels after 5, 8, and 9 days.
IMs receiving the same fixed-dose combination demonstrated re-established endoxifen
steady-state trough levels after 7, 10, and 11 days.
Discussion: The PBPK model impressively demonstrates the impact of drug holidays
in different CYP2D6 genotypes on PK. Population simulation results indicate that drug
holidays of more than 2 weeks cause a tremendous decrease of plasma levels despite
the long half-life of tamoxifen. To improve therapeutic success, PBPK modeling allows
identifying genotype-specific differences in PK following drug holidays and adequate
treatment with loading doses.
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INTRODUCTION
Tamoxifen treatment proved to be highly successful against
hormone receptor positive breast cancer (Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG), 2005). Recently, the
American Society of Clinical Oncology (ASCO) updated its
guidelines to recommend up to 10 years of adjuvant endocrine
therapy. This adds an additional benefit on breast cancer survival
for patients. Tamoxifen is characterized by excellent efficacy and
good tolerability and treatment for up to 10 years is feasible
(Burstein et al., 2014).
It is acknowledged that the formation of tamoxifen’s highly
active metabolite endoxifen depends on the activity of the
polymorphic enzyme cytochrome P450 2D6 (CYP2D6) (Brauch
et al., 2008, 2009; Mürdter et al., 2011; Maximov et al.,
2013). More than 100 alleles of CYP2D6 have already been
reported (http://www.cypalleles.ki.se/cyp2d6.htm). Patients with
the extensive metabolizer (EM) genotype show significantly
higher endoxifen steady-state levels than patients with an
intermediate metabolizer (IM) genotype than patients with a
poor metabolizer (PM) genotype, each undergoing tamoxifen
treatment with the standard dose of 20mg daily (Schroth et al.,
2007, 2009, 2010; Brauch et al., 2011, 2013a,b; Saladores et al.,
2013; Schwab et al., 2013). In addition, the metabolic pattern in
CYP2D6 EMs resulting out of standard tamoxifen is associated
with better treatment outcome (Schroth et al., 2009, 2010). This
led to the question how to improve tamoxifen treatment for
patients, irrespective of their CYP2D6 genotype. Physiologically
based pharmacokinetic (PBPK) modeling was used to address
the issue of CYP2D6-dependent formation of endoxifen out
of tamoxifen. PBPK-modeling separates substance-specific as
well as anatomical and physiological species-specific parameters
within a mechanistic framework of a generic PBPK model
structure (for reviews please refer to Willmann et al., 2003;
Nestorov, 2007). In the context of such a PBPK-model, the
influence of CYP2D6 enzyme activity on endoxifen PK was
already investigated. A fully coupled CYP2D6-genotype specific
whole-body PBPK model of tamoxifen, N-desmethyl-tamoxifen,
4-hydroxy-tamoxifen, and endoxifen was established which
provided valuable insight into the tamoxifen mass balance
(Dickschen et al., 2012). The model was further used to assess,
which dosing combinations are able to equalize endoxifen
exposure in CYP2D6 IMs and PMs compared to EMs undergoing
standard tamoxifen (20 mg/d) therapy. That approach resulted
in suggested fixed-dose combinations of tamoxifen (20 mg/d)
and CYP2D6 genotype-specific amounts of endoxifen for IMs
(1 mg/d) and PMs (3 mg/d). These combinations will now be
prospectively evaluated in a clinical intervention trial (Dickschen
et al., 2014; Figure 1 upper row).
Along with the introduced differences for the therapeutic
effect related to CYP2D6 genotype, patient adherence is a second
key factor influencing treatment benefit. It was reported that
patient adherence to tamoxifen progressively decreases over time,
especially after 1 year of treatment (Partridge, 2006; Ruddy and
Partridge, 2009; Ziller et al., 2009; Makubate et al., 2013). Thus,
the change in adjuvant endocrine treatment paradigm from
5 to 10 years will probably face decreasing patient adherence
as a problem. Decreased adherence is likely to occur more
often in patients of the CYP2D6 EM genotype i.e., the patients
that benefit most from standard tamoxifen treatment might
have an increased risk of decreased efficacy (Rae et al., 2009).
The fixed-dose combination of tamoxifen and endoxifen with
or without therapeutic drug monitoring could prove useful in
re-establishing steady-state kinetics following drug holidays in
CYP2D6 EM and IM patients (Figure 1 Group B). Investigating
the impact of drug holidays on tamoxifen PK in clinical
daily practice for patients of different CYP2D6 genotypes is
prone to erroneous conclusions. Patient adherence is difficult to
assess and patients tend to rate their compliance better than it
actually is. A prospective clinical trial investigating the impact
of drug holidays on tamoxifen kinetics in breast cancer patients
would expose patients with sub-therapeutic concentrations of
tamoxifen/endoxifen. Healthy volunteers would be exposed to
tamoxifen for an unacceptably long time (up to 12 months) due
to its long half-life. Therefore, such studies are almost impossible
to conduct due to ethical concerns.
Here, PBPK modeling provides a helpful tool to investigate
various drug-holiday scenarios. In addition, development of
steady-state kinetics under standard tamoxifen takes long,
especially achieving effective concentrations of the secondary
metabolite endoxifen. A fixed-dose combination of tamoxifen
and endoxifen (20 and 3 mg/d, respectively) could prove useful
in accelerating the establishment of the steady-state metabolic
pattern, too (Figure 1 Group A).
The presented work shows how genotype-specific PBPK
modeling can be used to address the relevant question of patient
adherence undergoing long-term therapy and the subsequent
impact on PK. Moreover, PBPK modeling opens the door for
minimizing the risk of decreased treatment benefit due to lack
of adherence when combined with therapeutic drug monitoring
as it enables for the calculation of individualized doses to re-
establish efficaciousmetabolic patterns in all patients, irrespective
of their genotype.
Genotype-specific fixed dose combinations for IMs and PMs
were shown to equalize endoxifen exposure at steady-state in
silico (Dickschen et al., 2014) (upper row). The fixed-dose
combination of 20mg tamoxifen and 3mg endoxifen following
this rationale is regarded as a standard for PMs, thus they were
no longer evaluated in this analysis. EMs and IMs are assumed to
be more prone to decreased adherence and can benefit from this
fixed-dose combination to accelerate time to endoxifen steady-
state trough levels. Drug holidays were simulated for a time of 2,
4, 8, or 12 weeks.
MATERIALS AND METHODS
The presented coupled PBPK model was developed by
means of the computational systems biology software
platform including PK-Sim R© 4.2.4 and MoBi R© 2.3.5
(www.systems-biology.com/products). PK-Sim R© also calculated
the PK-parameters from the simulation results. Population
simulations were conducted using the MoBi R© Toolbox for
MATLAB R© 2.2/2.3 (www.mathworks.com/products/matlab).
This tool was also used for the evaluation of simulation results
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FIGURE 1 | Virtual clinical trial simulation rationale and study plan. Ctss, steady-state trough concentration; EM, extensive metabolizer; IM, intermediate
metabolizer; PM, poor metabolizer.
in terms of plasma concentration-time profiles, goodness-of-fit
plots, box-whisker-plots, as well as calculation of median plasma
concentrations of the simulated compounds.
A virtual study with two groups was conducted. In
group A the time to development of endoxifen steady-state
kinetics in CYP2D6 EMs under standard therapy (20 mg/d)
and CYP2D6 IMs under fixed-dose combination (20 mg/d
tamoxifen, 1 mg/d endoxifen) was investigated. Time to steady-
state was the day before endoxifen Ctss of CYP2D6 EMs
was exceeded (cases) or the day when endoxifen Ctss of
CYP2D6 EMs was again achieved (controls). Results were
compared to CYP2D6 EMs and IMs under the fixed-dose
combination of 20 mg/d tamoxifen and 3 mg/d endoxifen.
Thus, in group A, controls consisted of CYP2D6 EMs
and IMs each receiving either standard tamoxifen (CYP2D6
EMs) or the CYP2D6 IM-specific fixed-dose combination
once daily (CYP2D6 IMs) to ensure equalized endoxifen
exposure in both genotypes. Cases consisted of CYP2D6 EMs
and IMs receiving the CYP2D6 fixed-dose combination of
20mg tamoxifen and 3mg endoxifen once daily. Population
simulations were conducted in each the four groups (N = 1000,
respectively).
In group B the impact of drug holidays in CYP2D6 EMs
and IMs after 6 months of tamoxifen was investigated. To
ensure equalized endoxifen exposure in both genotype groups
CYP2D6 EMs received standard tamoxifen and IMs received a
fixed-dose combination (20 mg/d tamoxifen, 1 mg/d endoxifen).
After 2, 4, 8, or 12 weeks of no drug intake administration
of standard tamoxifen (EMs, controls) or 20 mg/d tamoxifen
and 1 mg/d endoxifen (IMs, controls) were compared to
the intake of 20 mg/d tamoxifen and 3 mg/d endoxifen in
CYP2D6 EMs and IMs (cases). Thus, in group B, controls
consisted of CYP2D6 EMs and IMs each receiving standard
tamoxifen once daily (CYP2D6 EMs) or the CYP2D6 IM-
specific fixed-dose combination once daily (CYP2D6 IMs) for
6 months. Subsequently, drug holidays of different lengths was
simulated, namely for 2, 4, 8, and 12 weeks. Consequently,
drug intake was re-established in terms of CYP2D6 EMs
with standard tamoxifen once daily and in terms of CYP2D6
IMs with the CYP2D6 IM fixed-dose combination once daily
until 12 months of intake were completed. Cases were made
up of CYP2D6 EMs and IMs receiving standard tamoxifen
once daily (CYP2D6 EMs) or the CYP2D6 IM-specific fixed-
dose combination once daily (CYP2D6 IMs) for 6 months.
Frontiers in Pharmacology | www.frontiersin.org 3 March 2017 | Volume 8 | Article 67
Dickschen et al. Impact of Drug Holidays on Tamoxifen
Subsequently, drug holidays of different lengths was simulated,
namely drug holidays taken for 2, 4, 8, and 12 weeks.
Consequently, drug intake was re-established with CYP2D6
PM-specific fixed-dose combination in CYP2D6 EMs and IMs.
Population simulations were conducted in each group (N = 1000,
respectively).
The goal of the clinical trial simulation is to analyze
the time to target concentration of END either at therapy
onset or following drug holidays for CYP2D6 EMs and
IMs. To match END exposure in both groups, IMs received
their fixed dose combination of 20mg tamoxifen and 1mg
endoxifen whereas EMs remained under standard therapy.
Target concentration range in each study arm was the
endoxifen steady-state trough concentration (Ctss) observed
in CYP2D6 EMs receiving standard tamoxifen assuming full
adherence. Time to steady-state (either achievement or re-
establishment) was the day before endoxifen Ctss of CYP2D6
EMs was exceeded (cases) or the day when endoxifen Ctss
of CYP2D6 EMs was again achieved (controls). Overall,
20 different administration protocols in two study groups
were investigated in 20,000 virtual female patients. The
administration protocols investigated are illustrated in detail in
Table 1.
From all simulations, median Ctss concentrations and
percentiles were calculated. Target endoxifen Ctss is defined
as the median Ctss of endoxifen in 1,000 CYP2D6 EMs
receiving standard tamoxifen for 12 months assuming full
adherence.
RESULTS
Steady-state kinetics of tamoxifen and its main metabolites
following daily intake of 20mg tamoxifen in CYP2D6 EMs
take at least 4 months to develop (Figure 2). As endoxifen is
a major contributor to tamoxifen’s anti-tumoral activity, the
established fixed-dose combination of 20mg tamoxifen and
3mg endoxifen could be used in order to reduce the time to
endoxifen steady-state levels in CYP2D6 EMs. A comparison
between the case group receiving 20mg tamoxifen and 3mg
endoxifen, and the control group receiving 20mg tamoxifen,
shows that the case group reaches Ctss of endoxifen already
after 9 days (Figure 2A). In the control group, however,
Ctss of endoxifen is not reached before day 125 (Figure 2B).
Thus, administration of the fixed-dose combination in CYP2D6
EMs starting tamoxifen treatment is able to considerably
speed up the development of endoxifen Ctss by 116 days
(Figures 2A,B).
Steady-state kinetics of tamoxifen, N-desmethyltamoxifen, 4-
hydroxytamoxifen, and endoxifen following daily intake of 20mg
tamoxifen and 1mg endoxifen in CYP2D6 IMs take at least 10–11
TABLE 1 | Virtual clinical trial design for tamoxifen drug holidays and re-establishment of steady-state kinetics in CYP2D6 EMs and IMs.
Study Arm Run-In Phase Trial Phase
GROUP A Month 1–Month 6 Month 7–Month 12
CYP2D6 EM
Case 20mg TAM + 3.0mg END q.d. 20mg TAM + 3.0mg END q.d.
Control 20mg TAM q.d. 20mg TAM q.d.
CYP2D6 IM
Case 20mg TAM + 3.0mg END q.d. 20mg TAM + 3.0mg END q.d.
Control 20mg TAM + 1.0mg END q.d. 20mg TAM + 1.0mg END q.d.
GROUP B Month 1–Month 6 POST DRUG HOLIDAYS-MONTH 12
CYP2D6 EM
Case drug holidays 2 weeks 20mg TAM q.d. 20mg TAM + 3.0mg END q.d.
Case drug holidays 4 weeks 20mg TAM q.d. 20mg TAM + 3.0mg END q.d.
Case drug holidays 8 weeks 20mg TAM q.d. 20mg TAM + 3.0mg END q.d.
Case drug holidays 12 weeks 20mg TAM q.d. 20mg TAM + 3.0mg END q.d.
Control drug holidays 2 weeks 20mg TAM q.d. 20mg TAM q.d.
Control drug holidays 4 weeks 20mg TAM q.d. 20mg TAM q.d.
Control drug holidays 8 weeks 20mg TAM q.d. 20mg TAM q.d.
Control drug holidays 12 weeks 20mg TAM q.d. 20mg TAM q.d.
CYP2D6 IM
Case drug holidays 2 weeks 20mg TAM + 1.0mg END q.d. 20mg TAM + 3.0mg END q.d.
Case drug holidays 4 weeks 20mg TAM + 1.0mg END q.d. 20mg TAM + 3.0mg END q.d.
Case drug holidays 8 weeks 20mg TAM + 1.0mg END q.d. 20mg TAM + 3.0mg END q.d.
Case drug holidays 12 weeks 20mg TAM + 1.0mg END q.d. 20mg TAM + 3.0mg END q.d.
Control drug holidays 2 weeks 20mg TAM + 1.0mg END q.d. 20mg TAM + 1.0mg END q.d.
Control drug holidays 4 weeks 20mg TAM + 1.0mg END q.d. 20mg TAM + 1.0mg END q.d.
Control drug holidays 8 weeks 20mg TAM + 1.0mg END q.d. 20mg TAM + 1.0mg END q.d.
Control drug holidays 12 weeks 20mg TAM + 1.0mg END q.d. 20mg TAM + 1.0mg END q.d.
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FIGURE 2 | Simulated time to steady-state in CYP2D6 EMs receiving either standard tamoxifen (control) or the fixed-dose combination (case). Ctss of
TAM, NDM-TAM, 4-OHTAM, and END following a fixed-dose combination of 20mg tamoxifen and 3mg endoxifen in CYP2D6 EMs as a loading dose schedule (case)
compared to a control group of CYP2D6 EMs receiving standard tamoxifen. Results are benchmarked to median Ctss levels of all four compounds in CYP2D6 EMs
under standard tamoxifen (shaded areas, percentiles 5–95). (A) Simulation results in the case group receiving 20mg tamoxifen and 3mg endoxifen. (B) Simulation
results in the control group receiving 20mg tamoxifen. TAM, tamoxifen; N-DMTAM, N-desmethyltamoxifen; 4-OHTAM, 4-hydroxytamoxifen; END, endoxifen.
weeks to develop (Figure 3). A comparison between the case
group receiving 20mg tamoxifen and 3mg endoxifen and the
control group, receiving 20mg tamoxifen and 1mg endoxifen,
shows that the case group reaches Ctss of endoxifen after 13 days
(Figure 3A). In the control group, however, Ctss of endoxifen is
not reached before day 77 (Figure 3B). The administration of
the fixed-dose combination in CYP2D6 IMs starting tamoxifen
treatment is able to considerably speed up the development of
endoxifen Ctss by 54 days (Figures 3A,B).
Thus, CYP2D6 EMs receiving 20mg tamoxifen and 3mg
endoxifen achieve endoxifen Ctss 4 days earlier than CYP2D6 IMs
under the same treatment (Table 2).
The investigation of the impact of drug holidays on tamoxifen
PK was also simulated with the PBPKmodel. In the CYP2D6 EM
population, drug holidays of already 2 weeks lead to a decrease of
endoxifen trough concentration (Ct) to a range around the 25th
percentile of the median Ctss of endoxifen in CYP2D6 EMs under
standard tamoxifen with full adherence (Ct after 2 weeks drug
holidays: 14.9 µg/L vs. Ctss 25th percentile with full adherence:
13.8 µg/L) (Figure 4). Drug holidays exceeding 1 month lead to
a decrease of endoxifen Ct under the 5th percentile of endoxifen
Ctss in CYP2D6 EMs under standard tamoxifen assuming full
adherence. To accelerate the re-establishment of endoxifen Ctss
in CYP2D6 EMs taking drug holidays of 2 weeks, 1, 2, or 3
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FIGURE 3 | Simulated time to steady-state in CYP2D6 IMs receiving either standard tamoxifen and 1mg endoxifen (control) or standard tamoxifen and
3mg endoxifen (case). Ctss of TAM, NDM-TAM, 4-OHTAM, and END following a fixed-dose combination of 20mg tamoxifen and 3mg endoxifen in CYP2D6 IMs as
a loading dose schedule (case) compared to a control group of CYP2D6 IMs receiving standard tamoxifen and 1mg endoxifen. Results are benchmarked to median
Ctss levels of all four compounds in CYP2D6 EMs under standard tamoxifen (shaded areas, percentiles 5–95). (A) Simulation results in the case group receiving 20mg
tamoxifen and 3mg endoxifen. (B) Simulation results in the control group receiving 20mg tamoxifen and 1mg endoxifen. TAM, tamoxifen; N-DMTAM,
N-desmethyltamoxifen; 4-OHTAM, 4-hydroxytamoxifen; END, endoxifen.
months, the fixed-dose combination of 20mg tamoxifen and
3mg endoxifen was compared to the standard tamoxifen dose.
Patients with drug holidays of 2 weeks followed by the intake
of the fixed-dose combination of 20mg tamoxifen and 3mg
endoxifen show a re-establishment of endoxifen Ctss already after
2 days whereas patients receiving standard tamoxifen after 2
weeks of drug holidays only show a re-establishment of endoxifen
Ctss at day 307 which is day 126 post first-dose of re-starting
tamoxifen intake on day 182.
The situation pronouncedly worsened when drug holidays
of 1, 2, or 3 months were simulated (data not shown,
Table 2). Patients receiving the fixed-dose combination of
20mg tamoxifen and 3mg endoxifen demonstrate re-established
endoxifen Ctss after 5, 8, and 9 days of taking the fixed-dose
combination. However, patients taking only standard tamoxifen
after the drug holidays of 1, 2, or 3 months length, do not
exert endoxifen Ctss before day 336 which was end of simulation
time. Thus, re-establishment of endoxifen Ctss only by taking
standard tamoxifen following drug holidays takes at least 100
days following 1 month of no tamoxifen intake and probably
worsened with increasing length of no drug intake.
In the CYP2D6 IM population, drug holidays of 2 weeks
lead to a decrease of endoxifen Ct to a range lower than the
25th percentile of the median Ctss of endoxifen in CYP2D6
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TABLE 2 | Simulated time to endoxifen Ctss in CYP2D6 EMs and IMs under
the treatment ensuring comparable exposure in both groups (controls)
and the fixed-dose combination of 20mg tamoxifen and 3mg endoxifen
(cases).
Time to endoxifen
Ctss in CYP2D6 EMs
[days]
Time to endoxifen
Ctss in CYP2D6 IMs
[days]
STUDY GROUP A
Case 9 13
Control 125 77
STUDY GROUP B
Case drug holidays 2 weeks 2 4
Case drug holidays 4 weeks 5 7
Case drug holidays 8 weeks 8 10
Case drug holidays 12 weeks 9 11
Control drug holidays 2 weeks 126 40
Control drug holidays 4 weeks >100 55
Control drug holidays 8 weeks >100 65
Control drug holidays 12 weeks >100 68
EMs under standard tamoxifen with full adherence (Ct after
2 weeks drug holidays: 10.6 µg/L vs. Ctss 25th percentile with
full adherence: 13.8 µg/L; Figure 5). Drug holidays exceeding 1
month lead to a decrease of endoxifen Ct under the 5th percentile
of endoxifen Ctss in CYP2D6 EMs under standard tamoxifen with
full adherence.
To accelerate the re-establishment of endoxifen Ctss in
CYP2D6 IMs taking drug holidays of 2 weeks, 1, 2, or 3
months, the fixed-dose combination of 20mg tamoxifen and
3mg endoxifen was compared to the fixed-dose combination
of 20mg tamoxifen and 1mg endoxifen. Patients taking drug
holidays of 2 weeks followed by the intake of the fixed-dose
combination of 20mg tamoxifen and 3mg endoxifen show a
re-establishment of endoxifen Ctss already after 4 days. Patients
taking drug holidays of 2 weeks followed by the intake of 20mg
tamoxifen and 1mg endoxifen only show a re-establishment of
endoxifen Ctss at day 221 which is day 40 post first-dose of
re-starting tamoxifen intake on day 182.
The situation again pronouncedly worsened when drug
holidays of 1, 2, or 3 months were simulated. Patients receiving
the fixed-dose combination of 20mg tamoxifen and 3mg
endoxifen demonstrate re-established endoxifen Ctss after 7, 10,
and 11 days of taking the fixed-dose combination. Patients taking
only 20mg tamoxifen and 1mg endoxifen after the drug holidays
of 1, 2, or 3 months length only show endoxifen Ctss after 55, 65,
and 68 days.
Thus, CYP2D6 EMs receiving 20mg tamoxifen and 3mg
endoxifen achieve endoxifen Ctss 2 days earlier than CYP2D6
IMs under the same treatment, irrespective of the length of
drug holidays taken and simulated (Table 2). Moreover, time
to steady-state re-establishment in CYP2D6 EMs following
standard tamoxifen therapy takes longer than simulated,
exposing patients to sub-therapeutic endoxifen Ctss for at least
3–4 months following drug holidays of more than 4 weeks. This
gives a comparable picture when starting tamoxifen treatment
in CYP2D6 EMs under standard tamoxifen treatment. CYP2D6
IMs receiving the fixed-dose combination of 20mg tamoxifen
and 1mg endoxifen, leading to comparable endoxifen Ctss to
CYP2D6 EMs under 20mg tamoxifen need 6–9 weeks to re-
establish endoxifen benchmark Ctss.
DISCUSSION
For more than 40 years tamoxifen is now a cornerstone in the
armamentarium against early hormone receptor positive breast
cancer. Recently, adjuvant endocrine therapy paradigm has been
adapted and ASCO now recommends treating women for up to
10 years, either within a sequential therapy of tamoxifen and
aromatase inhibitors or even with tamoxifen alone. Tamoxifen
is known for its excellent efficacy and good tolerability, thus
treating patients for 10 years is feasible (Burstein et al., 2014).
However, patient adherence to long term therapy is known to
decrease over time and might represent a problem for treatment
efficacy (Partridge, 2006; McCowan et al., 2008; Ruddy and
Partridge, 2009; Ziller et al., 2009; Dezentje et al., 2010; Hershman
et al., 2010; Makubate et al., 2013). As tamoxifen metabolism
is prone to CYP2D6 activity, on top of the question how drug
holidays impact on tamoxifen PK in general, this is of special
interest for the different CYP2D6 genotypes in order to ensure
full efficacy for all patients receiving tamoxifen (Stearns et al.,
2003; Rae et al., 2009). The characteristic metabolite pattern
resulting from tamoxifen daily dosing of 20mg to CYP2D6 EMs
was demonstrated to be well tolerated and highly beneficial over
the past four decades (Early Breast Cancer Trialists’ Collaborative
Group (EBCTCG), 1992, 1998, 2005; Stearns et al., 2003, 2004).
However, steady-state kinetics of tamoxifen metabolites require a
very long period of time to develop which can be in the range of
3–4 months as demonstrated by our previously developed PBPK
model (Wu et al., 2009; Dickschen et al., 2012, 2014). It was
reported that endoxifen is the key contributor to tamoxifen’s anti-
tumoral activity exerting a concentration-dependent effect on
tumor proliferation and growth (Johnson et al., 2004; Lim et al.,
2005, 2006; Wu et al., 2009). Thus, the time to endoxifen Ctss is
likely to be relevant for the full therapeutic benefit of tamoxifen.
As it is well-described in literature that endoxifen formation out
of tamoxifen depends on CYP2D6 activity, time to endoxifen
Ctss and the level itself depend to a great extent on the CYP2D6
genotype (Stearns et al., 2003; Borges et al., 2006; Antunes et al.,
2012; Damodaran et al., 2012; Maximov et al., 2013; Saladores
et al., 2013).
The fixed-dose combination of 3mg endoxifen and 20mg
tamoxifen, originally intended to optimize treatment in CYP2D6
PMs by equalizing endoxifen steady-state exposure compared to
CYP2D6 EMs under standard tamoxifen, was used in simulations
to investigate the impact on time to endoxifen steady-state
levels in CYP2D6 EMs and IMs (Dickschen et al., 2012, 2014).
In the presented virtual clinical trial, population simulation
results demonstrate impressively that endoxifen steady-state
levels develop far more quickly when the fixed-dose combination
of 3mg endoxifen and 20mg tamoxifen was given to CYP2D6
EMs and IMs instead of standard tamoxifen to CYP2D6 EMs
(116 days more quickly) or 1mg endoxifen and 20mg tamoxifen
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FIGURE 4 | Simulated time to steady-state in CYP2D6 EMs receiving either standard tamoxifen (control) or the fixed-dose combination (case)
following drug holidays after 2 weeks. Ctss of TAM, NDM-TAM, 4-OHTAM, and END following a fixed-dose combination of 20mg tamoxifen and 3mg endoxifen
in CYP2D6 EMs as a loading dose schedule (case) after a 2-week drug holiday compared to a control group of CYP2D6 EMs receiving standard tamoxifen. Results
are benchmarked to median Ctss levels of all four compounds in CYP2D6 EMs under standard tamoxifen (shaded areas, percentiles 5–95). (A) Simulation results in
the case group receiving 20mg tamoxifen and 3mg endoxifen. (B) Simulation results in the control group receiving 20mg tamoxifen. TAM, tamoxifen; N-DMTAM,
N-desmethyltamoxifen; 4-OHTAM, 4-hydroxytamoxifen; END, endoxifen.
to CYP2D6 IMs (54 days more quickly). It was chosen to
administer the previously published fixed-dose combination of
1mg endoxifen and 20mg tamoxifen daily as a control dose
to the CYP2D6 IMs in this virtual clinical trial in order to
achieve comparable endoxifen Ctss for all CYP2D6 genotypes
(Dickschen et al., 2014). The presented results nicely outline
that CYP2D6 EMs and IMs can achieve the effective endoxifen
exposure faster when they start tamoxifen treatment with the
fixed-dose combination of 20mg tamoxifen and 3mg endoxifen.
Here, a time of 10 days would be sufficient for CYP2D6 EMs
based on simulation results and 2 weeks for CYP2D6 IMs. After
this loading dose schedule, the optimal tamoxifen treatment
schedule would be 20mg tamoxifen for CYP2D6 EMs and 1mg
endoxifen and 20mg tamoxifen for CYP2D6 IMs according to
previously published simulation results. Following this published
individualized tamoxifen treatment rationale, CYP2D6 PMs
would receive 20mg tamoxifen and 3mg endoxifen as a standard
regimen. Thus, they were not longer part of this specific analysis.
Another big concern in adjuvant endocrine long-term therapy
is patient adherence and persistence to treatment (Partridge,
2006; Barron et al., 2007; McCowan et al., 2008; Rae et al.,
2009; Ruddy and Partridge, 2009; Ziller et al., 2009; Dezentje
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FIGURE 5 | Simulated time to steady-state in CYP2D6 IMs receiving either standard tamoxifen and 1mg endoxifen (control) or the fixed-dose
combination of standard tamoxifen and 3mg endoxifen (case) following drug holidays after 2 weeks. Ctss of TAM, NDM-TAM, 4-OHTAM, and END
following a fixed-dose combination of 20mg tamoxifen and 3mg endoxifen in CYP2D6 IMs as a loading dose schedule (case) after a 2-week drug holiday compared
to a control group of CYP2D6 IMs receiving standard tamoxifen and 1mg endoxifen. Results are benchmarked to median Ctss levels of all four compounds in
CYP2D6 EMs under standard tamoxifen (shaded areas, percentiles 5–95). (A) Simulation results in the case group receiving 20mg tamoxifen and 3mg endoxifen.
(B) Simulation results in the control group receiving 20mg tamoxifen and 1mg endoxifen. TAM, tamoxifen; N-DMTAM, N-desmethyltamoxifen; 4-OHTAM,
4-hydroxytamoxifen; END, endoxifen.
et al., 2010; Hershman et al., 2010; Makubate et al., 2013).
This is by now of special importance for adjuvant endocrine
treatment as tamoxifen treatment duration is likely to increase
from 5 to 10 years and patient adherence is known to decrease
over time (Hershman et al., 2010). Moreover, it was reported
that especially in CYP2D6 EMs discontinuation of tamoxifen
treatment is more likely than in patients with impaired CYP2D6
enzyme activity (Rae et al., 2009). A potential reason could
be an increased rate of adverse events such as hot flushed in
CYP2D6 EMs. Thus, paradoxically adherence in patients most
likely to benefit to a far greater extent from standard tamoxifen
treatment is worse than in patients less likely to receive full
benefit of regular tamoxifen treatment, i.e., with an impaired
CYP2D6 enzyme activity. However, it is very difficult to estimate
patient adherence in investigational clinical trials as self-reported
adherence pronouncedly deviates from true patient adherence
(Ziller et al., 2009). Here, the developed and qualified PBPK
model provided a very useful tool to investigate the impact
of drug holidays in CYP2D6 EMs and IMs on plasma levels.
Population simulation results in 20,000 virtual subjects indicate
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that drug holidays of more than 2 weeks cause a tremendous
decrease of plasma levels of all four substances investigated
despite the long half-life of tamoxifen (Fuchs et al., 1996).
Steady-state levels of endoxifen are not re-established before 100
days of intake of 20mg tamoxifen in the CYP2D6 EM groups
following drug holidays of 2 weeks or more. In the CYP2D6
IM control group, patients show re-established endoxifen steady-
state levels after 40, 55, 65, or 68 days following drug holidays
of 2 weeks, 1, 2, or 3 months and subsequent intake of 1mg
endoxifen and 20mg tamoxifen, respectively. Thus, CYP2D6
EMs are renderedwith subtherapeutic endoxifen levels for at least
3–4 months following drug holidays of 4 weeks and more and
CYP2D6 IMs for 6 weeks or more assuming that they already
receive an fixed-dose combination of 1mg endoxifen and 20mg
tamoxifen to equalize their endoxifen Ctss to the one observed
in CYP2D6 EMs under standard tamoxifen. In both case groups,
CYP2D6 EMs and CYP2D6 IMs, the intake of 3mg endoxifen
and 20mg tamoxifen significantly speeds up the re-establishment
of endoxifen steady-state levels. CYP2D6 EMs show endoxifen
steady-state levels after 2, 5, 8, or 9 days following 2 weeks, 1, 2,
or 3 of drug holidays and subsequent intake of 3mg endoxifen
and 20mg tamoxifen, respectively. CYP2D6 IMs show endoxifen
steady-state levels after 4, 7, 10, or 11 days following 2 weeks,
1, 2, or 3 months of drug holidays and subsequent intake of
3mg endoxifen and 20mg tamoxifen. Consequently, the time of
subtherapeutic endoxifen Ctss in both genotype groups is reduced
to <2 weeks even when patients stop intake for 3 months which
is usually the time frame between two prescriptions. Due to the
decreased endogenous endoxifen formation out of the standard
dose of tamoxifen, CYP2D6 IMs take in general 2 days longer
to re-establish endoxifen Ctss when receiving exactly the same
fixed dose combination as CYP2D6 EMs. This demonstrates the
impact of the CYP2D6 genotype on endoxifen formation once
more and is well in line with current knowledge about CYP2D6
activity as a PK-relevant prognostic factor in tamoxifen treatment
(Brauch et al., 2013a).
The fixed-dose combination of 3mg endoxifen and 20mg
tamoxifen is thus not only useful for optimizing tamoxifen
treatment in CYP2D6 PMs as proposed previously but can be
also very useful in optimizing tamoxifen treatment of CYP2D6
EMs and IMs with decreased adherence (Rae et al., 2009;
Dickschen et al., 2014). The virtual clinical trial impressively
demonstrates the differing impact of drug holidays on PK
in patients with distinct CYP2D6 genotypes. The application
of the fixed-dose combination of tamoxifen and endoxifen
in CYP2D6 EMs and IMs however might be supported by
therapeutic drug monitoring of patients to determine plasma
concentration levels of tamoxifen and its metabolites as self-
reported patient adherence is most likely not representative for
true adherence and plasma concentration levels of tamoxifen
and endoxifen should determine the use and duration of the
proposed fixed-dose combination. Overall, this investigation
demonstrates the value of PBPK simulations in situations
where clinical studies are almost impossible to conduct taking
into account the impact of different genotypes on PK.
The simulations provide guidance for clinical investigations
with the opportunity to optimize endocrine therapy with
the potential to improve clinical outcome in breast cancer
patients.
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